Neubond

Neubond is a London-based medical device company spun out of Imperial College London's Department of Bioengineering. The company targets a fundamental obstacle in stroke recovery: patients attempting to move often cannot perceive whether their muscles are activating, which undermines the neural feedback loop the brain needs to restore motor function. By closing that gap, Neubond's platform aims to make rehabilitation both more effective and more sustainable.

The company's core product is a compact wearable bracelet that uses embedded sensors to pick up faint electromyographic signals from the forearm, even when patients cannot feel or see any movement. When activation is detected, a companion app shows the patient in real time that their muscle has responded — providing the sensory feedback that reinforces the brain's attempt to rebuild the connection between the intent to move and the physical response. Clinicians access the same platform remotely to set rehabilitation programmes, track exercise frequency, measure contraction quality, and monitor patient progress, reducing the need for in-person visits.

Prior to its seed round, Neubond developed its technology with over £720,000 in grant funding, including a European Research Council Proof-of-Concept award. A 15-patient pilot study recorded a 30% improvement in range of motion after one month. The company is running a clinical feasibility study at Charing Cross Hospital and is working towards MHRA medical device certification and a future randomised controlled trial. In June 2026, Neubond raised £1.5 million in a seed round led by Waseda University Ventures, alongside SFC Capital and New Wave Ventures. The team has six full-time staff.